[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100057318":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":16,"responsibleParty":7,"collaborators":7,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":7,"eligibilityCriteria":121,"healthyVolunteers":117,"sex":122,"minAge":123,"maxAge":7,"enrollmentInfo":124,"targetDuration":7,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":141,"whyStopped":7,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":7,"leadSponsor":148,"locationsCount":150},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12,14],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Lamivudine\u002FZidovudine",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Capravirine",{"type":10,"name":15,"description":7,"armGroupLabels":7,"otherNames":7},"Nelfinavir mesylate",[17,30,39,48,57,67,77,87,95,105],{"facility":18,"status":7,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Clin Research of West Florida","Clearwater","Florida","33765","United States","US",{"type":25,"coordinates":26},"Point",[27,28],-82.8001,27.96585,{"lat":28,"lon":27},{"facility":31,"status":7,"city":32,"state":20,"zip":33,"country":22,"countryCode":23,"cosmosGeoPoint":34,"geoPoint":38,"contacts":7},"Community Health Care","Fort Lauderdale","33306",{"type":25,"coordinates":35},[36,37],-80.14338,26.12231,{"lat":37,"lon":36},{"facility":40,"status":7,"city":41,"state":20,"zip":42,"country":22,"countryCode":23,"cosmosGeoPoint":43,"geoPoint":47,"contacts":7},"South Shore Hosp","Miami","33139",{"type":25,"coordinates":44},[45,46],-80.19366,25.77427,{"lat":46,"lon":45},{"facility":49,"status":7,"city":50,"state":20,"zip":51,"country":22,"countryCode":23,"cosmosGeoPoint":52,"geoPoint":56,"contacts":7},"Infectious Diseases Associates","Sarasota","34239",{"type":25,"coordinates":53},[54,55],-82.53065,27.33643,{"lat":55,"lon":54},{"facility":58,"status":7,"city":59,"state":60,"zip":61,"country":22,"countryCode":23,"cosmosGeoPoint":62,"geoPoint":66,"contacts":7},"AIDS Research Consortium of Atlanta","Atlanta","Georgia","30308",{"type":25,"coordinates":63},[64,65],-84.38798,33.749,{"lat":65,"lon":64},{"facility":68,"status":7,"city":69,"state":70,"zip":71,"country":22,"countryCode":23,"cosmosGeoPoint":72,"geoPoint":76,"contacts":7},"Beth Israel Deaconess Med Ctr","Boston","Massachusetts","02215",{"type":25,"coordinates":73},[74,75],-71.05977,42.35843,{"lat":75,"lon":74},{"facility":78,"status":7,"city":79,"state":80,"zip":81,"country":22,"countryCode":23,"cosmosGeoPoint":82,"geoPoint":86,"contacts":7},"Catholic Med Ctr","Jamaica","New York","11432",{"type":25,"coordinates":83},[84,85],-73.80569,40.69149,{"lat":85,"lon":84},{"facility":88,"status":7,"city":80,"state":80,"zip":89,"country":22,"countryCode":23,"cosmosGeoPoint":90,"geoPoint":94,"contacts":7},"Liberty Medical","10014",{"type":25,"coordinates":91},[92,93],-74.00597,40.71427,{"lat":93,"lon":92},{"facility":96,"status":7,"city":97,"state":98,"zip":99,"country":22,"countryCode":23,"cosmosGeoPoint":100,"geoPoint":104,"contacts":7},"Anderson Clinical Research","Pittsburgh","Pennsylvania","15221",{"type":25,"coordinates":101},[102,103],-79.99589,40.44062,{"lat":103,"lon":102},{"facility":106,"status":7,"city":107,"state":7,"zip":7,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":7},"Immunity Care and Research Inc","Santo Domingo","Dominican Republic","DO",{"type":25,"coordinates":111},[112,113],-69.89232,18.47186,{"lat":113,"lon":112},"100057318","phase-2-safety-and-effectiveness-of-a-new-anti-hiv-drug-ag1549-in-combination-with-other-anti-hiv-drugs-in-hiv-infected-patients-100057318",false,"NCT00004998","Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients","A Phase II, Open-Label Study of AG1549 in Combination With Other Antiretroviral Agents in Treatment-Naive HIV-Infected Patients","Inclusion Criteria\n\nPatients may be eligible if they:\n\n* Are HIV-positive.\n* Are at least 18 years old.\n* Have a CD4 cell count of more than 50 cells\u002Fmm3.\n* Have an HIV level of more than 5000 copies\u002Fml.\n\nExclusion Criteria\n\nPatients will not be eligible if they:\n\n* Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.\n* Have taken an experimental drug within 28 days of study entry.","ALL","18 Years",{"count":125,"type":7},30,"INTERVENTIONAL",[128],"PHASE2","The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.",[131],"HIV Infections",[133,134,135,136,137,138,139,140],"Drug Therapy, Combination","Zidovudine","HIV Protease Inhibitors","Lamivudine","Reverse Transcriptase Inhibitors","Anti-HIV Agents","Nelfinavir","Combivir","SUSPENDED","2005-06-23",{"date":144,"type":145},"2005-06-24","ESTIMATED",{"date":147,"type":7},"1999-11",{"name":149,"class":6},"Agouron Pharmaceuticals",10]